Abstract | BACKGROUND: METHODS: A total of 373 subjects were randomized to receive placebo (n=126), istradefylline 20 mg/day (n=123), or istradefylline 40 mg/day (n=124). The primary efficacy variable was the change in daily OFF time. Other secondary variables were also evaluated. RESULTS: The change in daily OFF time was significantly reduced in the istradefylline 20 mg/day (-0.99 hours, P=.003) and istradefylline 40 mg/day (-0.96 hours, P=.003) groups compared with the placebo group (-0.23 hours). The most common adverse event was dyskinesia (placebo, 4.0%; istradefylline 20 mg/day, 13.0%; istradefylline 40 mg/day, 12.1%). CONCLUSIONS:
Istradefylline reduced daily OFF time and was well tolerated in Japanese PD patients with motor complications on levodopa treatment.
|
Authors | Yoshikuni Mizuno, Tomoyoshi Kondo, Japanese Istradefylline Study Group |
Journal | Movement disorders : official journal of the Movement Disorder Society
(Mov Disord)
Vol. 28
Issue 8
Pg. 1138-41
(Jul 2013)
ISSN: 1531-8257 [Electronic] United States |
PMID | 23483627
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2013 Movement Disorder Society. |
Chemical References |
- Adenosine A2 Receptor Antagonists
- Purines
- istradefylline
|
Topics |
- Adenosine A2 Receptor Antagonists
(therapeutic use)
- Aged
- Dose-Response Relationship, Drug
- Double-Blind Method
- Female
- Humans
- Japan
- Male
- Middle Aged
- Parkinson Disease
(drug therapy)
- Purines
(therapeutic use)
- Retrospective Studies
- Treatment Outcome
|